ProfileGDS5678 / 1418520_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 71% 69% 72% 73% 58% 61% 71% 68% 69% 71% 70% 66% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3132170
GSM967853U87-EV human glioblastoma xenograft - Control 24.5238471
GSM967854U87-EV human glioblastoma xenograft - Control 34.2402469
GSM967855U87-EV human glioblastoma xenograft - Control 44.6316772
GSM967856U87-EV human glioblastoma xenograft - Control 54.6724973
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5995858
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7118661
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.4575471
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1279668
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.316369
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4516471
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3827670
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.998366
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4099771